AnnJi Pharmaceutical
Taipei, Taiwan· Est.
Taiwan biotech developing first‑in‑class small‑molecule therapies for neurology, immunology and fibrosis.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech developing first‑in‑class small‑molecule therapies for neurology, immunology and fibrosis.
NeurologyDermatologyImmunologyFibrosis
Technology Platform
Proprietary small‑molecule discovery platform integrating high‑throughput synthesis, structure‑based design, and functional pharmacology to generate first‑in‑class NCEs.
Opportunities
Advancement of first‑in‑class small‑molecule candidates into early clinical trials and potential orphan‑drug incentives could unlock significant valuation upside.
Risk Factors
Heavy reliance on external financing and the high attrition rate of early‑stage drug development pose substantial execution risks.
Competitive Landscape
AnnJi competes with both large pharma and niche biotech firms developing HDAC6 inhibitors and anti‑fibrotic agents; differentiation hinges on its novel chemistry platform and orphan‑drug focus.